Trevi Therapeutics, Inc.

NasdaqGM TRVI

Trevi Therapeutics, Inc. Dividend Yield on February 05, 2025

Trevi Therapeutics, Inc. Dividend Yield is NA on February 05, 2025, a NA change year over year. Dividend yield measures the dividend per share relative to stock's price value; higher yield suggests higher dividend return.

Trevi Therapeutics, Inc. 52-week high Dividend Yield is 0.00% on January 16, 2025, which is NA below the current Dividend Yield.
Trevi Therapeutics, Inc. 52-week low Dividend Yield is 0.00% on January 16, 2025, which is NA below the current Dividend Yield.
Trevi Therapeutics, Inc. average Dividend Yield for the last 52 weeks is 0.00%.

Key data

Date	Dividend Yield	Free Cash Flow Yield	Earnings Yield	Enterprise Value (EV)

NasdaqGM: TRVI

Trevi Therapeutics, Inc.

CEO	Ms. Jennifer L. Good
IPO Date	May 7, 2019
Location	United States
Headquarters	195 Church Street
Employees	27
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Personal Care

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Key trends

Past 5 years